bioRxiv (Cold Spring Harbor Laboratory) · 2023 · 10 citations · 28 references
Life SciencesBiochemistryMedicinal ChemistryEnzymologyPost-translational ModificationProtein-protein InteractionsLigand BindingProtein-ligand BindingCovalent Protein BindingElectrophilic ReactivityMedicinal Chemistry ApplicationsTargeted Protein DegradationTernary Complex Formation
ABSTRACT Small molecules that can induce protein degradation by inducing proximity between a desired target and an E3 ligase have the potential to greatly expand the number of proteins that can be manipulated pharmacologically. Current strategies for targeted protein degradation are mostly limited in their target scope to proteins with preexisting ligands. Alternate modalities such as molecular glues, as exemplified by the glutarimide class of ligands for the CUL4 CRBN ligase, have been mostly discovered serendipitously. We recently reported a trans -labelling covalent glue mechanism which we named ‘Template-assisted covalent modification’, where an electrophile decorated small molecule binder of BRD4 was effectively delivered to a cysteine residue on an E3 ligase DCAF16 as a consequence of a BRD4-DCAF16 protein-protein interaction. Herein, we report our medicinal chemistry efforts to evaluate how various electrophilic modifications to the BRD4 binder, JQ1, affect DCAF16 trans -labeling and subsequent BRD4 degradation efficiency. We discovered a decent correlation between the ability of the electrophilic small molecule to induce ternary complex formation between BRD4 and DCAF16 with its ability to induce BRD4 degradation. Moreover, we show that a more solvent-exposed warhead presentation is optimal for DCAF16 recruitment and subsequent BRD4 degradation. Unlike the sensitivity of CUL4 CRBN glue degraders to chemical modifications, the diversity of covalent attachments in this class of BRD4 glue degraders suggests a high tolerance and tunability for the BRD4-DCAF16 interaction. This offers a potential new avenue for a rational design of covalent glue degraders by introducing covalent warheads to known binders.
28
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Krönke, Namrata D. Udeshi, Anupama Narla et al. · Science · 2013 · 1.8K citations · Full text
Medicine, Cell Biology, Oncology +14
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu, Richard E. Middleton, Huahang Sun et al. · Science · 2013 · 1.6K citations · Full text
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Eric S. Fischer, Kerstin Böhm, John R. Lydeard et al. · Nature · 2014 · 1.1K citations · Full text
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Jan Krönke, Emma C. Fink, Paul W. Hollenbach et al. · Nature · 2015 · 836 citations · Full text